[CAS NO. 233254-24-5] Tomeglovir
PRODUCTS SPECIFICATIONS [233254-24-5]
DESCRIPTION [233254-24-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 441.54 |
| Molecular Formula | C23H27N3O4S |
| SMILES | CC(C)(CO)C(NC1=CC=C(NS(=O)(C2=C3C=CC=C(N(C)C)C3=CC=C2)=O)C=C1)=O |
Summary
Tomeglovir is a potent anti- CMV agent, inhibiting processing of viral DNA-concatemers, with IC 50 s of 0.34 μM and 0.039 μM for HCMV and MCMV.
IC50 & Target
IC50: 0.34 μM (HCMV), 0.039 μM (MCMV) [1]
In Vitro
Tomeglovir (BAY 38-4766) is a potent anti-CMV agent, with IC 50 s of 0.34 μM and 0.039 μM for HCMV and MCMV. Tomeglovir also suppresses HELF and NIH 3T3 cells, with CC 50 s of 85 μM and 62.5 μM, respectively [1] . Tomeglovir (BAY 38-4766) inhibits HCMV Davis and various monkey CMV strains with EC 50 s of 1.03 ± 0.57 μM and < 1 μM [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Tomeglovir (BAY 38-4766; 3, 10, 30, 100 mg/kg, p.o.) dose-dependently reduces MCMV-DNA in salivary glands, livers and kidneys of MCMV-infected NOD-SCID mice, and prolongs the survival of the mice. Tomeglovir (10, 25 and 50 mg/kg) shows antiviral activity in the hollow fiber mouse model [1] . Tomeglovir (BAY 38-4766) shows antiviral activity in SCID mice with MCMV, and the LD 50 is >2000 mg/kg in mice and rats [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 108 mg/mL ( 244.60 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.2648 mL | 11.3240 mL | 22.6480 mL |
| 5 mM | 0.4530 mL | 2.2648 mL | 4.5296 mL |
| 10 mM | 0.2265 mL | 1.1324 mL | 2.2648 mL |
References
- [1] Weber O, et al. Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. Antiviral Res. 2001 Mar;49(3):179-89.
- [2] Reefschlaeger J, et al. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother. 2001 Dec;48(6):757-67.